Medium in Medical Technology

Stem Cell Sciences Announces the Creation of the World's First Authentic Rat Embryonic Stem Cells from its Exclusively Licensed Technology

... exclusive rights to commercialise the rat ES cells, the specific culture medium used to generate and grow the cells, and rats derived therefrom. The ... Riddell, Chief Executive Officer of Stem Cell Sciences. The culture medium patent family (PCT/GB2007/001163), which is filed in multiple territories ...

Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System

... System, Echo's next-generation, needle-free, non-invasive skin permeation medium for its Symphony(TM) tCGM System, a novel transdermal continuous glucose ... events, indicating strong reliability of Prelude as the skin permeation medium for Symphony. About Echo Therapeutics Echo Therapeutics is focused on ...

DIA Annual Meeting Attendees Invited to Participate in Electronic Data Capture (EDC) Clinical Trial Survey

... TechTeam Global, Inc. TechTeam Global, Inc. is a leading provider of IT outsourcing and business process outsourcing services to large and medium businesses, as well as government organizations. The company's primary services include service desk, technical support, desk-side support, security ...

Freezing Prostate Cancer Does a Man's Body Good

... levels of prostate-specific antigen (PSA) in the blood. Of those patients, 112 (93 percent) had no evidence of cancer -- in spite of 72 being labeled medium to high risk for cancer recurrence. "There were no local recurrences in the areas we treated, and with the ability to re-treat the 7 percent of ...

Novel Therapeutic Approaches May Transform Treatment and Improve Patient Outcomes in Several Platelet Disorders

... transfusion. Patients were randomized to receive one of three platelet-transfusion dosing regimens: a low dose (1.1 x 10^11 platelets/m^2), a medium dose (2.2 x 10^11 platelets/m^2), or a high dose (4.4 x 10 ^11 platelets/m^2). An acceptable dose of platelets could be within 25 percent (lower or ...

Minster Pharmaceuticals Plc Announces Positive Results from Phase II Trial of Migraine with Aura

... the treatment of chronic schizophrenia. Minster's near-term focus is on the development and commercialization of its current pipeline. Its medium term strategy is to leverage the anticipated cashflows from the current pipeline by in-licensing further compounds with the ultimate objective of ...

Technique for Rapidly Reprogramming Adult Cells Into Stem Cells Published in PLoS Biology

... media range, which is being bought and used by researchers to establish pure and stable populations of authentic ES cells. SCS' Culticell iSTEM(TM) medium was launched earlier this year and is part of SCS' stem cell culture media business, which provides a growing and important revenue source for the ...

Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress

... To celebrate its 20-year milestone, Bayer launched the "It's Your Passion. Let It Out" contest. Applicants from around the world expressed -- in the medium of their choice -- what they are passionate about as members of the hemophilia community. Representatives of the WFH served as contest judges and ...

Dutch Top Institute Allocates 150 Million Euro to R&D Projects Targeting Early Diagnosis and Treatment of Disease

... Alzheimer's disease and various types of cancer. With the joint expertise of the best Dutch scientists and R&D groups in major industry and small and medium enterprises we can expect new important scientific breakthroughs, that will not only have a major clinical, but also an economic impact," says Prof. ...

New Implantable Lenses Can Reduce the Need for Glasses After Cataract Surgery

... and Treating Eye Disease explains that the older types of plastic lenses help people see well at one distance -- be it close up, far away, or at a medium distance. Two newer types of lenses, accommodating and multifocal, let the eye focus at varying distances, so fewer patients need glasses for reading ...

Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting

... effectiveness of medications evaluated in different studies for the same condition. In general, effect sizes are categorized as small (0.2), medium (0.5) and large (0.8). An analysis of the phase III pivotal study in pediatric patients with Attention Deficit Hyperactivity Disorder (ADHD) showed ...

Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells

... oxygen environment. The device "sandwiches" the stem cells with oxygen from two sources, one from the top with air diffusing through the culture medium and the second from the bottom with air diffusing through a silicon membrane mixed with perfluorocarbon, a very powerful oxygen reservoir. "The use ...

Targanta Reports Improved Ability of Oritavancin to Stop Bacteria Growth In Vitro Compared With Other Glycopeptide Antibiotics

... ORI MICs for S. pneumoniae were identical with and without P80, likely as a result of LHB present in the microbiological culture medium for the pneumococcus. In addition, plates with low-binding surfaces demonstrated 4- to 8-fold reductions in ORI MICs without ...

Access Pharmaceuticals Announces Poster Presentations on ProLindac at the American Association for Cancer Research 2007 Annual Meeting

... associated with antitumor activity. Intracellular concentrations of platinum in HCT-116 tumor cells were about 10-fold greater when the incubating medium pH was lowered from 7.0 to 5.4. Previously Access had shown a faster release of platinum as pH is lowered in a simple aqueous system. This study ...

PTC Therapeutics Announces Additional Positive Interim Phase 2 Results of PTC124 in Duchenne Muscular Dystrophy

... Overall, four of the six, or 67 percent, of patients treated at the lower dose level and 10 of the 20, or 50 percent, of patients treated at the medium dose level demonstrated an increase in the expression of dystrophin post-treatment. Response did not appear to be dependent on type of nonsense ...

Successful Human Clinical Trial of Chrono Therapeutic's Drug/Device Combination Product - ChronoDose

... using its model drug compound. The dose escalation trial showed statistically significant modulation and control of the dosing profiles. Using low, medium and high concentrations, for 16 hours, the model drug permeated each subject's skin on multiple occasions, resulting in clear and distinct peaks and ...

Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents

... mg/kg), 0.58 (0.05 to 0.08 mg/kg), 1.19 (0.09 to 0.12 mg/kg), and 1.34 (0.13 to 0.17 mg/kg). In general, effect sizes are categorized as small (0.2), medium (0.5) and large (0.8). In the second short-term trial, 304, investigators examined 1 mg, 2 mg, 3 mg and 4 mg doses and placebo during nine weeks ...

Surfaxin (Lucinactant) Long-Term Survival Advantage vs. Comparators Published in Pediatrics

... of Pediatrics, publishes papers on original research or observations and special feature articles in the field of pediatrics. Pediatrics serves as a medium for expression to the general medical profession as well as pediatricians. The Executive Board and Officers of the American Academy of Pediatrics ...

Archimedes Pharma Presents Positive Efficacy and Safety Data on Nasalfent at European Association for Palliative Care Congress

... pain, is in phase III clinical development and is targeted for launch in 2009. To provide further impetus and sales growth for the company in the medium term, Archimedes has an established development organisation with proprietary enabling technologies for nasal drug delivery and a number of products ...

Immunoassay Systems - Your Laboratory Workhorse

... testing to occur at the bedside or physicians office, the central laboratory is hardly threatened with extinction. National volume data suggest that medium and large labs are busier than ever before, and the huge range of their capabilities, gold standard reliability and ability to handle very large ...

When Volume Matters, Immunoassay Systems Deliver

... testing to occur at the bedside or physicians office, the central laboratory is hardly threatened with extinction. National volume data suggest that medium and large labs are busier than ever before, and the huge range of their capabilities, gold standard reliability and ability to handle very large ...